Gosal Stephanie, Besri Nanda Notario, Dilogo Ismail Hadisoebroto
Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
J Clin Orthop Trauma. 2024 Jul 4;54:102492. doi: 10.1016/j.jcot.2024.102492. eCollection 2024 Jul.
Several preservative treatment options are available for the early stages of avascular necrosis of the femoral head (ANFH) but are not as effective as in the advanced-stages. The management of Ficat stage III-IV AFNH is limited to the high rate of patients being converted to total hip replacement (THR). Four female patients with Ficat stage III-IV ANFH were included in this study, with a median age of 32.5 (20-40 years) and different risk factors. All four patients underwent open reduction and internal fixation with dynamic hip screw, transtrochanteric rotational osteotomy (TRO), and 7.5 mL secretome implantation from the allogeneic umbilical cord. With a median follow-up of 24.25 months (8-45 months), the patients showed an increment in Harris hip score and a decrement in visual analog scale during the follow-up period, except for one patient. Only the fourth patient with high disease activity of systemic lupus erythematosus and a long period of corticosteroid consumption progressed into collapsed, infected, and converted to THR. Combining TRO with secretome implantation is an effective alternative for advanced Ficat stages of ANFH patients. However, uncontrolled autoimmune conditions might interfere with the efficacy of the combination treatment and worsen the prognosis.
对于股骨头缺血性坏死(ANFH)的早期阶段,有几种保髋治疗方案可供选择,但效果不如晚期显著。Ficat III-IV期股骨头缺血性坏死的治疗方式有限,因为有很高比例的患者最终需要接受全髋关节置换术(THR)。本研究纳入了4例Ficat III-IV期ANFH女性患者,中位年龄为32.5岁(20-40岁),且具有不同的风险因素。所有4例患者均接受了切开复位内固定术,使用动力髋螺钉、经转子旋转截骨术(TRO),并植入7.5 mL来自异体脐带的分泌组。中位随访时间为24.25个月(8-45个月),除1例患者外,其余患者在随访期间Harris髋关节评分有所提高,视觉模拟评分有所降低。只有第4例患有高疾病活动度的系统性红斑狼疮且长期使用皮质类固醇的患者病情进展为股骨头塌陷、感染,最终接受了全髋关节置换术。对于Ficat晚期的ANFH患者,TRO联合分泌组植入是一种有效的替代治疗方法。然而未得到控制的自身免疫性疾病可能会干扰联合治疗的疗效并使预后恶化。